



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Max Gordon, Marina García, Teghesti Teclab, Wanda Christ, Mattias Forsell, Mia Phillipson, Peter Nilsson, Sara Mangsbo, Sophia Hober, Mikael Åberg, Jonas Klingström, Charlotte Thålin
charlotte.thalin@ki.se

Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, 182 88 Stockholm, Sweden (KB, UM, SHa, NGN, MGo, CT); Public Health Agency of Sweden, Stockholm, Sweden (KB, MGa, TT, JK); Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden (MGa, WC, JK); Department of Clinical Microbiology, Umeå University, Umeå, Sweden (MF); Department of Medical Cell Biology and SciLifeLab (MP), Department of Pharmacy and SciLifeLab (SM), and Department of Medical Sciences, Clinical Chemistry and SciLifeLab (MÅ), Uppsala University, Uppsala, Sweden; Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden (PN, SHo)

- 1 Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet* 2022; **399**: 234–36.
- 2 Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination. *N Engl J Med* 2022; **386**: 1088–91.
- 3 Rudberg A-S, Havervall S, Månberg A, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. *Nat Commun* 2020; **11**: 5064.
- 4 Havervall S, Marking U, Greilert-Norin N, et al. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. *Clin Transl Immunology* 2022; **11**: e1388.
- 5 Marking U, Havervall S, Norin NG, et al. High rate of BA.1, BA.1.1 and BA.2 infection in triple vaccinated. *medRxiv* 2022; published online April 3. <https://doi.org/10.1101/2022.04.02.2273333>.
- 6 Lustig Y, Gonen T, Meltzer L, et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. *Nat Immunol* 2022; published online May 9. <https://doi.org/10.1038/S41590-022-01212-3>.
- 7 Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. *Nat Biotechnol* 2020; **38**: 1073–78.

Vaccination plus previous infection: protection during the omicron wave in Brazil

As of May 11, 2022, an estimated 519 million individuals have been infected with SARS-CoV-2, and at least 11 billion COVID-19 vaccine doses

have been administered worldwide. Therefore, understanding hybrid immunity (ie, immunity derived from infection plus vaccination) is crucial to guide future vaccination policies. We found that vaccination provided additional protection to that induced by past infection during the gamma (P.1) and delta (B.1.617.2) variant waves of the pandemic in Brazil.¹ With the emergence of the omicron (B.1.1.529) variant, vaccine effectiveness appears to decay,^{2,3} but protection in individuals who have been previously infected and vaccinated remains unknown. We analysed the effect of hybrid immunity in preventing infection and severe outcomes during circulation of the omicron variant in Brazil.

Using national databases, we did a test-negative case-control study as previously described.¹ Cases were defined as individuals with positive RT-PCR or lateral-flow tests and controls as individuals with negative RT-PCR or lateral-flow tests between Jan 1 and March 22, 2022—a period during which omicron was the predominant variant in Brazil (appendix pp 2–4). Severe outcomes were defined as a positive test obtained from 14 days before to 3 days after hospital admission or death occurring within 28 days after a positive test. We analysed vaccine effectiveness in individuals who had been previously infected using two reference groups: unvaccinated with or without previous infection. Individuals could have more than one test included in these analyses, and each test was separately counted as a case or control. Detailed methods, including full inclusion and exclusion criteria, are in the appendix (p 2).

Of 9 266 235 tests from 8 471 561 individuals registered on surveillance databases during the study period, 918 219 tests from 899 050 individuals were eligible for inclusion in our analyses. 476 901 (51.9%) of 918 219 tests from 468 804 (52.1%) of 899 050 individuals

were positive and defined as cases, and 441 318 (48.1%) tests from 430 246 (47.9%) individuals were negative and defined as controls; 323 704 (35.2%) tests were from individuals who were unvaccinated (22 935 [2.4%] with and 300 769 [32.8%] without previous infection; appendix pp 6–7). Compared with those who were unvaccinated without previous infection, the effectiveness of past infection in preventing reinfection during the omicron wave was low (28.9% [95% CI 26.9–30.9]), increasing with vaccination with any vaccine type (Ad26.COV2.S [Johnson & Johnson], BNT162b2 [Pfizer–BioNTech], ChAdOx-1 nCoV-19 [Oxford–AstraZeneca], or CoronaVac [Sinovac Biotech]), especially after a booster dose, although this protection waned over time (appendix pp 5, 8). Protection against severe outcomes after a previous infection was relatively high (85.6% [95% CI 82.7–88.0]), increasing with vaccination (vaccine effectiveness ranging from 88.0% to 100%; appendix pp 5, 8). Compared with unvaccinated individuals with a previous infection, vaccination with previous infection showed a moderate increase in protection against symptomatic infection ranging from 7.3% (95% CI 4.0–10.4) to 62.7% (61.0–64.3), once again waning over time, and substantial protection against severe outcomes after the booster (appendix pp 5, 8–9). Similar results were obtained using a matched analysis by date of test (within 10 days), age (5-year bands), municipality of residence, and sex in a ratio of 1:2 (with replacement; appendix pp 10–12).

In summary, during a period when omicron was the dominant SARS-CoV-2 variant in Brazil, robust protection against severe disease was offered by a previous infection, and this was increased with hybrid immunity. However, against symptomatic infection, even boosted

For COVID-19 case and vaccination data see <https://coronavirus.jhu.edu/map.html>

See Online for appendix



Published Online
May 16, 2022
[https://doi.org/10.1016/S1473-3099\(22\)00288-2](https://doi.org/10.1016/S1473-3099(22)00288-2)

individuals with hybrid immunity had low levels of protection and protection waned over time. Booster doses in previously infected individuals offered a moderate but transient increase in protection against symptomatic infection and a slight improvement against severe outcomes. These data highlight an issue of whether future efforts should focus on preventing symptomatic infection or severe disease, considering the moderate and transient increase in protection offered by boosters against symptomatic infection and the likely endemicity of SARS-CoV-2.

MB-N reports grants from the *Fazer o bem faz bem* programme from JBS. VdAO, VSB, MLB, and MB-N are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured

products to the Ministry of Health for public health use. ESP is funded by the Wellcome Trust (grant number 213589/Z/18/Z). GLW is funded by the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (grant number E-26/210.180/2020). GLW, MLB, VSB, and MB-N are research fellows from CNPq, the Brazilian National Research Council. All other authors declare no competing interests.

*Thiago Cerqueira-Silva,
Vinicius de Araujo Oliveira,
Enny S Paixão,
Pilar Tavares Veras Florentino,
Gerson O Penna, Neil Pearce,
Guilherme L Werneck,
Maurício L Barreto,
Viviane S Boaventura,
Manoel Barral-Netto
manoel.barral@fiocruz.br

LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil (TC-S, VSB, MB-N); Universidade Federal da Bahia, Salvador, Bahia, Brazil (TC-S, VdAO, MLB, VSB, MB-N); Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz, Fiocruz,

Salvador, Bahia 40296-710, Brazil (VdAO, PTVF, MLB); London School of Hygiene & Tropical Medicine, London, UK (ESP, NP); Instituto de Ciências Biomédicas, University of Sao Paulo, Sao Paulo, Brazil (PTVF); Núcleo de Medicina Tropical, Universidade de Brasília. Escola Fiocruz de Governo, Fiocruz, DF, Brazil (GOP); Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (GLW); Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (GLW)

- 1 Cerqueira-Silva T, Andrews JR, Boaventura VS, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. *Lancet Infect Dis* 2022; published online March 31. [https://doi.org/10.1016/S1473-3099\(22\)00140-2](https://doi.org/10.1016/S1473-3099(22)00140-2).
- 2 Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. *N Engl J Med*; **386**: 1532–46.
- 3 Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against omicron and delta hospitalisation: test negative case-control study. *medRxiv* 2022; published online April 1. <https://doi.org/10.1101/2022.04.01.22273281> (preprint).